Indeed, pre-treatment of orthotopic PDAC (KPC + PSC co-inoculated) mice with a lysyl oxidase-like 2 (LOXL2) inhibitor disrupted collagen alignment without altering content, softened tumor tissue, and improved the therapeutic efficacy of nab-paclitaxel [265]. This evidence concerns the gene LOXL2 and neoplasm.